Literature DB >> 29018300

Vaxchora: The First FDA-Approved Cholera Vaccination in the United States.

Juan F Mosley, Lillian L Smith, Patricia Brantley, Dustin Locke, Madison Como.   

Abstract

Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection. Cholera, a potentially life-threatening bacterial infection that occurs in the intestines and causes severe diarrhea and dehydration, has a low incidence in the U.S., but a high incidence in Africa, Southeast Asia, and other locations around the world. These areas draw travelers from the U.S., so cholera can present in patients who return from visits to these regions. Previous means of prophylaxis included the use of doxycycline for the prevention of traveler's diarrhea, but doxycycline is not specific for cholera. With the approval of Vaxchora, a live attenuated, single-dose, oral suspension vaccine, travelers can now visit these areas with less chance of contracting the bacterium Vibrio cholerae, which causes cholera infections.

Entities:  

Keywords:  Vaxchora; bacterial infections; cholera; international travel; vaccination

Year:  2017        PMID: 29018300      PMCID: PMC5614415     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  3 in total

Review 1.  An evaluation of current cholera treatment.

Authors:  Sujit Kumar Bhattacharya
Journal:  Expert Opin Pharmacother       Date:  2003-02       Impact factor: 3.889

2.  Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.

Authors:  Wilbur H Chen; Mitchell B Cohen; Beth D Kirkpatrick; Rebecca C Brady; David Galloway; Marc Gurwith; Robert H Hall; Robert A Kessler; Michael Lock; Douglas Haney; Caroline E Lyon; Marcela F Pasetti; Jakub K Simon; Flora Szabo; Sharon Tennant; Myron M Levine
Journal:  Clin Infect Dis       Date:  2016-03-21       Impact factor: 9.079

3.  Updated global burden of cholera in endemic countries.

Authors:  Mohammad Ali; Allyson R Nelson; Anna Lena Lopez; David A Sack
Journal:  PLoS Negl Trop Dis       Date:  2015-06-04
  3 in total
  11 in total

1.  An overview of VaxchoraTM, a live attenuated oral cholera vaccine.

Authors:  Tarun Saluja; Vijayalaxmi V Mogasale; Jean-Louis Excler; Jerome H Kim; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2019-09-20       Impact factor: 3.452

Review 2.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

Review 3.  Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development.

Authors:  Zhidong Hu; Shui-Hua Lu; Douglas B Lowrie; Xiao-Yong Fan
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

4.  Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.

Authors:  Julie Liao; Jacob A Gibson; Bradley S Pickering; Paula I Watnick
Journal:  mSphere       Date:  2018-06-06       Impact factor: 4.389

Review 5.  Noninvasive vaccination against infectious diseases.

Authors:  Zhichao Zheng; Diana Diaz-Arévalo; Hongbing Guan; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2018-05-17       Impact factor: 3.452

6.  Strong Inhibition of Cholera Toxin B Subunit by Affordable, Polymer-Based Multivalent Inhibitors.

Authors:  Diksha Haksar; Eyleen de Poel; Linda Quarles van Ufford; Sumati Bhatia; Rainer Haag; Jeffrey Beekman; Roland J Pieters
Journal:  Bioconjug Chem       Date:  2019-01-24       Impact factor: 4.774

Review 7.  Travelers' Diarrhea: A Clinical Review.

Authors:  Alexander K C Leung; Amy A M Leung; Alex H C Wong; Kam L Hon
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

8.  Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview.

Authors:  Calman A MacLennan; Anastazia Older Aguilar; A Duncan Steele
Journal:  Clin Infect Dis       Date:  2019-12-09       Impact factor: 9.079

Review 9.  Human challenge trials in vaccine development.

Authors:  Amrita Sekhar; Gagandeep Kang
Journal:  Semin Immunol       Date:  2020-11-29       Impact factor: 11.130

Review 10.  Malaria vaccines: facing unknowns.

Authors:  Nirianne Marie Q Palacpac; Toshihiro Horii
Journal:  F1000Res       Date:  2020-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.